PT-141 (Bremelanotide)

Also: Bremelanotide, PT 141, PT141, Bremelanotide acetate

Melanocortin PeptideModerateBremelanotide (PT-141) has progressed from in-vitro and preclinical study into human clinical trials and has a regulatory development history in some jurisdictions tied to a specific, narrowly defined indication; that pharmaceutical regulatory status is distinct from research-use-only material and is neither described nor endorsed here. Within a research-use-only context the compound functions as a reference and tool for studying melanocortin-receptor signaling. The available literature spans mechanistic, animal-model, and human clinical work, and each observation should be read with attention to which type of evidence supports it. Much of the broader supporting literature remains preclinical or mechanistic.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

PT-141 is a common research designation for bremelanotide, a synthetic cyclic peptide in the melanocortin family that is structurally related to alpha-melanocyte-stimulating hormone (alpha-MSH) and associated with the melanotan analog lineage. In the research literature it is described as an agonist at melanocortin receptors, with particular interest in the centrally expressed MC3R and MC4R subtypes. Unlike many research peptides, bremelanotide has been examined in human clinical trials in addition to preclinical and mechanistic work, although the available findings should be interpreted conservatively in light of study design and preclinical-to-human translation limitations. This profile is an educational, research-use-only reference; it is not guidance for use in humans or animals and makes no claim regarding safety, efficacy, or any outcome.

Mechanism as described in the literature

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide within the melanocortin family, structurally related to alpha-melanocyte-stimulating hormone (alpha-MSH) and associated with the melanotan analog lineage. In the research literature it is characterized as a non-selective agonist at melanocortin receptors, with mechanistic interest concentrated on the centrally expressed MC4R and MC3R subtypes, which signal through G-protein-coupled receptor pathways. These are receptor-level descriptions drawn from the literature and do not describe any outcome, application, or use.

Mechanistic and preclinical work situates melanocortin signaling within several central pathways that the research literature associates with arousal, appetite and energy balance, and pigmentation; these are domains of ongoing study of the melanocortin system rather than asserted effects of this peptide. Because the receptor activity is described as non-selective across subtypes, attributing any specific physiological response to a single pathway is difficult, and the extent to which receptor-level observations translate into defined outcomes remains uncertain and requires careful interpretation due to species differences, study design, and the limits of preclinical-to-human translation.

Research areas

Melanocortin receptor (MC3R/MC4R) pharmacology and G-protein-coupled receptor signaling
Central nervous system pathways that the research literature associates with arousal, studied in animal and clinical models
Appetite and energy-homeostasis signaling within the melanocortin system (preclinical and mechanistic)
Cardiovascular and hemodynamic observations, including transient blood-pressure changes reported in controlled study settings and requiring expert interpretation
Structure-activity relationships across the alpha-MSH and melanotan analog family

Known limitations

Despite a clinical trial record, much of the supporting literature is mechanistic or preclinical and does not establish broad or generalizable conclusions.
The melanocortin agonism described for this peptide is reported as non-selective across receptor subtypes, which complicates attributing any specific observation to a single pathway.
Reported physiological observations (for example, transient blood-pressure changes and pigmentation-related findings) are noted in controlled study settings and require expert interpretation; they are not safety, efficacy, or outcome claims.
Findings from animal models and in-vitro systems do not necessarily translate to humans.
The pharmaceutical regulatory status of bremelanotide in some jurisdictions is distinct from research-use-only material and should not be read as applicable to research-supply compounds.
In research-supply contexts, compound identity, purity, and characterization vary between sources and require independent documentation and analytical testing visibility; no such data are asserted here.

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

Is PT-141 the same thing as bremelanotide?+

Yes. "PT-141" is a common research designation for bremelanotide, a synthetic melanocortin-receptor-agonist peptide related to alpha-MSH. Terminology varies between sources, and any naming should be verified against primary references during editorial review.

What does the research literature describe about PT-141 at the molecular level?+

It is described as an agonist at melanocortin receptors, with particular mechanistic interest in the MC3R and MC4R subtypes that participate in central G-protein-coupled signaling. These are receptor-level descriptions only; this profile does not describe outcomes, applications, or any form of use in humans or animals.

How strong is the evidence for PT-141?+

Relative to many research peptides, bremelanotide has an unusually developed human clinical record, but the evidence still requires conservative interpretation given non-selective receptor activity, study-design constraints, and preclinical-to-human translation limitations. References are intentionally left empty here for human editorial verification, and no safety or efficacy claim is made.

At a glance

Evidence level: Moderate
Research status: Bremelanotide (PT-141) has progressed from in-vitro and preclinical study into human clinical trials and has a regulatory development history in some jurisdictions tied to a specific, narrowly defined indication; that pharmaceutical regulatory status is distinct from research-use-only material and is neither described nor endorsed here. Within a research-use-only context the compound functions as a reference and tool for studying melanocortin-receptor signaling. The available literature spans mechanistic, animal-model, and human clinical work, and each observation should be read with attention to which type of evidence supports it. Much of the broader supporting literature remains preclinical or mechanistic.
Category: Melanocortin Peptide
Aliases: Bremelanotide, PT 141, PT141

Research & education only. Not medical advice; no dosing, administration, or use guidance. Learn more